These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 18680689)

  • 1. [Pharmacogenetics of antiretroviral therapy 2008: toward personalized treatment?].
    Vidal Marsal F
    Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 6():1-3. PubMed ID: 18680689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of adverse effects due to antiretroviral drugs.
    Vidal F; Gutiérrez F; Gutiérrez M; Olona M; Sánchez V; Mateo G; Peraire J; Viladés C; Veloso S; López-Dupla M; Domingo P
    AIDS Rev; 2010; 12(1):15-30. PubMed ID: 20216907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity.
    Martin AM; Nolan D; Gaudieri S; Phillips E; Mallal S
    Pharmacogenomics; 2004 Sep; 5(6):643-55. PubMed ID: 15335286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspectives on pharmacogenomics of antiretroviral medications and HIV-associated comorbidities.
    Haas DW; Tarr PE
    Curr Opin HIV AIDS; 2015 Mar; 10(2):116-22. PubMed ID: 25565175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The pharmacogenetics of response to antiretroviral therapy].
    Rodríguez-Nóvoa S; Soriano Vázquez V
    Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 6():10-7. PubMed ID: 18680691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacogenetics of antiretroviral drugs].
    Dragović G; Grbović L; Jevtović D
    Vojnosanit Pregl; 2012 Dec; 69(12):1091-6. PubMed ID: 23424964
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of antiretroviral therapy on immunity in patients infected with HIV.
    Feola DJ; Thornton AC; Garvy BA
    Curr Pharm Des; 2006; 12(9):1015-22. PubMed ID: 16515483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative pharmacogenomics of antiretroviral and cytotoxic treatments.
    Stebbing J; Bower M
    Lancet Oncol; 2006 Jan; 7(1):61-8. PubMed ID: 16389185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Will pharmacogenomic discoveries improve HIV therapeutics?
    Haas DW
    Top HIV Med; 2005; 13(3):90-5. PubMed ID: 16170225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence-resistance relationships to combination HIV antiretroviral therapy.
    Bangsberg DR; Kroetz DL; Deeks SG
    Curr HIV/AIDS Rep; 2007 May; 4(2):65-72. PubMed ID: 17547827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV pharmacogenomics: closer to personalized therapy?
    Payne DA; Bryant BJ;
    Am J Pharmacogenomics; 2004; 4(3):141-50. PubMed ID: 15174895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Host determinants of antiretroviral drug activity.
    Boffito M; Winston A; Owen A
    Curr Opin Infect Dis; 2005 Dec; 18(6):543-9. PubMed ID: 16258330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What's next? Treatment options when the first antiretroviral regimen fails virologically or is not tolerated, Part 2.
    Ruane PJ; Daar ES
    AIDS Read; 2004 Sep; 14(9):487-98. PubMed ID: 15457602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of the pharmacogenetics of HIV therapy.
    Rodríguez-Nóvoa S; Barreiro P; Jiménez-Nácher I; Soriano V
    Pharmacogenomics J; 2006; 6(4):234-45. PubMed ID: 16462814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of gender and calendar year on time to and duration of virologic suppression among antiretroviral-naïve HIV-infected individuals initiating combination antiretroviral therapy.
    Raboud J; Blitz S; Walmsley S; Thompson C; Rourke SB; Loutfy MR;
    HIV Clin Trials; 2010; 11(6):340-50. PubMed ID: 21239362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug interactions with antiretrovirals.
    Catanzaro LM; Slish JC; DiCenzo R; Morse GD
    Curr HIV/AIDS Rep; 2004 Jun; 1(2):89-96. PubMed ID: 16091228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of first-line antiretroviral therapy and acquired drug resistance among HIV-1-infected children in India.
    Shet A; Neogi U; Sahoo PN; De Costa A
    Pediatr Infect Dis J; 2013 May; 32(5):e227-9. PubMed ID: 23249907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antiviral treatment regimens].
    Esser S
    Hautarzt; 2006 Nov; 57(11):961-2, 964-8. PubMed ID: 17053925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition.
    Michaud V; Bar-Magen T; Turgeon J; Flockhart D; Desta Z; Wainberg MA
    Pharmacol Rev; 2012 Jul; 64(3):803-33. PubMed ID: 22759796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs.
    Calcagno A; Cusato J; D'Avolio A; Bonora S
    Clin Pharmacokinet; 2017 Apr; 56(4):355-369. PubMed ID: 27641153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.